What is your preferred BTK inhibitor for patients with relapsed/refractory mantle cell lymphoma?

The majority of patients with relapsed/refractory MCL will respond to single agent BTKi therapy and this is my preferred treatment in patients at first relapse when a clinical trial is not available, and they have not been exposed to a BTKi (for example, on a frontline clinical trial). I often used ...

That is a tough one. I have largely moved away from ibrutinib given the side effect profile. Though, I should add that if I have a patient on chronic therapy tolerating without significant side effects, I do not change therapy. With regards to second generation BTKi's, I have been giving more zanubr...

Zanbrutinib